Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes

Prabakaran, Mookkan; Kumar, Sachin; Venkatachalam, Ashok Raj Kattur; Wu, Xiapeng; He, Fang; Zhou, Jiyong; Kwang, Jimmy

doi:10.1016/j.antiviral.2014.06.017

Cited by 16 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recombinant PrV expressing the NA gene derived from a swine A(H1N1) influenza virus only protected pigs to a limited extent. 129,130 A recombinant PrV HA n/a H5N1 168,169 Baculo HA n/a H1N1, H5N1, H6N8, H7N9, H9N2 [171][172][173][174][175][176][177][178] PIV-5 HA n/a H3N2, H5N1, H7N9 [180][181][182] NP n/a H5N1 182 HA n/a H7N9 181 HA/NP n/a H7N9 181 HA n/a H3N2 179 expressing HA from a swine A(H3N2) virus was tested in mice and induced protective immunity against infection with heterologous A (H3N2) virus. 131 An attenuated strain of equine herpesvirus (EHV-1), an alphaherpesvirus that infects horses, has an impressive safety record in horses and other mammalian species and therefore should be considered an attractive vaccine vector.…”

Section: Herpes Virus Vectorsmentioning

confidence: 99%

“…175,176 Finally, recombinant baculoviruses expressing HA genes of A(H6), A(H7) and A(H9) influenza viruses were capable of inducing protective immunity against infection with homologous viruses in mice. [177][178][179] Although recombinant baculovirus vector vaccines were tested in mice, efficacy data in other animal models is still lacking. Short-term production of baculovirus-based influenza virus vaccines for use in clinical trials is therefore not likely.…”

Section: Baculovirus Vectorsmentioning

confidence: 99%

See 1 more Smart Citation

Viral vector-based influenza vaccines

Vries

Rimmelzwaan

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Antigenic drift of seasonal influenza viruses and the occasional introduction of influenza viruses of novel subtypes into the human population complicate the timely production of effective vaccines that antigenically match the virus strains that cause epidemic or pandemic outbreaks. The development of game-changing vaccines that induce broadly protective immunity against a wide variety of influenza viruses is an unmet need, in which recombinant viral vectors may provide. Use of viral vectors allows the delivery of any influenza virus antigen, or derivative thereof, to the immune system, resulting in the optimal induction of virus-specific B- and T-cell responses against this antigen of choice. This systematic review discusses results obtained with vectored influenza virus vaccines and advantages and disadvantages of the currently available viral vectors.

show abstract

Section: Herpes Virus Vectorsmentioning

confidence: 99%

Section: Baculovirus Vectorsmentioning

confidence: 99%

Viral vector-based influenza vaccines

Vries

Rimmelzwaan

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…A series of reports in which surface display strategy was used to obtain rAcMNPV particles, demonstrated the protective efficacy of rAcMNPV. [175][176][177][178][179][180] In these works, virions of rAcMNPV exhibited HA from different strains of influenza virus, together with GP64, and evidence supported the protective efficacy of the i.n. route of immunization after challenge.…”

Section: Influenza Virusmentioning

confidence: 86%

Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations

Fragoso-Saavedra

Vega-Lopez

2020

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Over 90% of pathogens of medical importance invade the organism through mucosal surfaces, which makes it urgent to develop safe and effective mucosal vaccines and mucosal immunization protocols. Besides, parenteral immunization does not provide adequate protective immunity in mucosal surfaces. Effective mucosal vaccination could protect local and systemic compartments and favor herd immunity. Although various mucosal adjuvants and Ag‐delivery systems have been developed, none has filled the gap to control diseases caused by complex mucosal pathogens. Among the strategies to counteract them, recombinant virions from the baculovirus Autographa californica multiple nucleopolyhedrovirus (rAcMNPV) are useful vectors, given their safety and efficacy to produce mucosal and systemic immunity in animal infection models. Here, we review the immunogenic properties of rAcMNPV virions from the perspectives of mucosal immunology and vaccinology. Some features, which are analyzed and extrapolated from studies with different particulate antigens, include size, shape, surface molecule organization, and danger signals, all needed to break the tolerogenic responses of the mucosal immune tissues. Also, we present a condensed discussion on the immunity provided by rAcMNPV virions against influenza virus and human papillomavirus in animal models. Through the text, we highlight the advantages and limitations of this experimental immunization platform.

show abstract

“…Different HA subtypes have been displayed on baculovirus. These subtypes include H1N1 (Prabakaran et al, 2011;Sim et al, 2016), H5N1 (Yang et al, 2007;Jin et al, 2008;Prabakaran et al, 2008;Wu et al, 2009;Tang et al, 2010;Hu et al, 2012;Ge et al, 2016), H6N8 (Musthaq et al, 2014), H7N7 (Rajesh Kumar et al, 2013), H7N9 (Prabakaran et al, 2014), and H9N2 . Other type I membrane proteins from human pathogens displayed on baculovirus as vaccine immunogens include envelope (E) glycoprotein from Japanese encephalitis virus ( JEV) (Xu et al, 2011) and Spike (S) protein from SARS-CoV (Feng et al, 2006).…”

Section: Examples Of Using Surface-display Strategies In Vaccinationmentioning

confidence: 99%

Baculovirus as Versatile Vectors for Protein Display and Biotechnological Applications

Tsai¹,

Wei²,

Lo³

et al. 2020

Current Issues in Molecular Biology

View full text Add to dashboard Cite

The baculovirus-insect cell system has long been deployed for a variety of applications including for use as biopesticides, for recombinant protein production, transient transgene expression, tissue therapy, and for vaccine production. Apart from the advantage of large-scale heterologous protein production with appropriate eukaryotic post-translational modification, foreign proteins can also be displayed on the viral envelope. This surface-display technology preserves the native multimeric structure of the protein, thereby expanding the clinical and pharmaceutical utility of the baculovirus system. Recombinant baculoviruses displaying major antigens for human or animal viruses can serve as appropriate vaccines. They can also serve as effective diagnostic platforms and various cell-based assay systems. In this review, we discuss progress in applying baculovirus surfacedisplay, including protein display on the envelope, capsid, and occlusion bodies of baculoviruses, as well as on cells. We will also describe strategies for improvement of this biotechnological approach.

show abstract

Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes

Cited by 16 publications

References 35 publications

Viral vector-based influenza vaccines

Viral vector-based influenza vaccines

Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations

Baculovirus as Versatile Vectors for Protein Display and Biotechnological Applications

Contact Info

Product

Resources

About